脂质体纳米药物制剂的生物分析方法及药代动力学研究进展

Research progress in bioanalysis and pharmacokinetics of liposome nanomedicine

脂质体纳米药物制剂是一种被脂双分子层囊泡结构包裹的具有纳米尺度的新型药物制剂。脂质体作为药物递送载体,具备生物相容性良好、在体内可被生物降解以及定位靶向性强等优点。应用脂质体纳米药物递送系统,可在一定程度上改善某些药物在人体内的药代动力学行为及药效,减轻不良反应。脂质体纳米药物进入人体后,会释放游离型药物,因而体内会同时存在负载型脂质体纳米药物和游离型药物。负载型药物是药物的贮库,游离型药物与药物的药效和不良反应有关,因此,脂质体药代动力学研究应该同时关注负载型药物和游离型药物。游离药物、脂质体粒子及其材料的精准分析是脂质体体内定量研究的一个难点。本篇综述介绍了脂质体纳米药物的前处理方法,总结了脂质体纳米药物的生物分析方法及其药代动力学的研究进展,希望能够为脂质体纳米药物制剂的研究开发提供参考。

Liposome nanomedicine is a new drug preparation with nano scale,which is encapsulated by lipid bilayer vesicle structure.As a drug delivery carrier,liposome has many advantages such as good biocompatibility,biodegradation in vivo and strong targeting.The application of liposome nano drug delivery system can improve the pharmacokinetic behavior and efficacy of some drugs in vivo to a certain extent,and reduce toxic and side effects.After liposome nanomedicine enter into the body,free drugs will be released,so there will be loaded drugs and free drugs in the body.Loaded drugs are drug repositories,free drugs are related to their efficacy and adverse reactions.Therefore,the pharmacokinetics study of liposomes should focus on both loaded drugs and free drugs.Quantitative analysis of free drugs,liposome particles and their materials is a big challenge.The bioanalysis and pharmacokinetics of liposome nanomedicines will be introduced and discussed in this review.We hope this review will provide a reference for the development of liposome nanomedicine.